"The first and second phase of clinical trials of the vaccine developed by AstraZeneca and Oxford University will begin in China before the end of the year," TASS quoted AstraZeneca Deputy President for the Asia-Pacific Region Leon Wang.
It is noted that in 2021 AstraZeneca plans to submit an application to the PRC authorities for the release of the vaccine for free sale on the local market.
At the moment, the company has received approval to conduct clinical trials from the authorities of Brazil, the UK, the USA, South Africa and Japan.
On October 20, it became known that China is conducting clinical trials of 13 vaccines against coronavirus infection COVID-19, four of which are in the third stage of research.